GlassScriptPhysician profile
Amanda Amberg
NPI 1053904813
$4,992.22
in general payments reported to CMS, 2019-2025
25 companies · $2,318 in 2025
The $2,318 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $663 · 2022: $972 · 2023: $176 · 2024: $864 · 2025: $2,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,358.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $1,669.94 | 2025 | M22 |
| Johnson & Johnson Vision Care, INC. | $567.00 | 2021-2024 | Acuvue |
| Bausch & Lomb Americas INC. | $447.36 | 2022-2025 | Miebo, Infuse, Vyzulta |
| Alcon Vision LLC | $394.13 | 2021-2025 | Tryptyr |
| Biotissue Holdings INC. | $364.41 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $290.21 | 2021-2025 | |
| Coopervision INC. | $203.13 | 2021-2024 | Misight Contact Lens, Onefit Contact Lens |
| Dompe US, INC. | $168.01 | 2024-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $131.37 | 2021 | |
| Aerie Pharmaceuticals, INC. | $115.77 | 2021 | |
| Abbvie INC. | $93.65 | 2023-2025 | Alphagan P, Lumigan |
| Topcon Healthcare, INC. | $83.34 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $82.68 | 2024-2025 | Xdemvy |
| Allergan, INC. | $67.78 | 2021 | |
| Harrow Eye, LLC | $55.37 | 2024-2025 | Vevye |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $53.19 | 2025 | Acthar |
| Rxsight INC | $34.36 | 2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Thea Pharma INC. | $28.42 | 2022-2025 | Iyuzeh |
| Oyster Point Pharma, INC. | $26.40 | 2025 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $23.17 | 2022 | |
| Genentech USA, INC. | $22.79 | 2025 | Vabysmo |
| Glaukos Corporation | $21.61 | 2024 | Idose |
| Johnson & Johnson Surgical Vision, INC. | $20.39 | 2024 | Tecnis Iol |
| Astellas Pharma US INC | $15.60 | 2024 | Izervay |
| Sight Sciences, INC. | $12.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Amberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.